LizaCoscaVillaruzMD

Oncology • Pittsburgh, PA

Associate Professor, Medicine, University of Pittsburgh School of Medicine

Join to view full profile

Dr. Villaruz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Villaruz's full profile

Already have an account?

Office
5150 Centre Avenue
Pittsburgh, PA 15232
Phone+1 412-623-7833

Fax+1 412-648-6579

Education & Training

UPMC Medical EducationFellowship, Hematology and Medical Oncology, 2008 - 2011
UPMC Medical EducationResidency, Internal Medicine, 2005 - 2008
University of Maryland School of MedicineClass of 2005

Certifications & Licensure

PA State Medical License 2005 - 2026
American Board of Internal Medicine Medical Oncology

Clinical Trials

Detection of Genetic Markers of Lung Cancer Start of enrollment: 1996 Jun 01
Recruiting
Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR) Start of enrollment: 2012 Dec 11
Completed
Phase 2
Single Arm on the Tolerability of Weekly Nab-paclitaxel Start of enrollment: 2013 Jun 25
Completed
Phase 2
Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases Start of enrollment: 2015 Dec 01
Terminated
Phase 2
Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Start of enrollment: 2017 Jul 05
Completed
Phase 2
A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer Start of enrollment: 2016 May 11
Completed
Phase 2
A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients Start of enrollment: 2017 Apr 04
Completed
Phase 2
Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC) Start of enrollment: 2017 Jul 18
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Phase I trial of ATR inhibitor elimusertib with FOLFIRI in advanced or metastatic gastrointestinal malignancies (ETCTN 10406).
Anuradha Krishnamurthy, Hong Wang, John C Rhee, Diwakar Davar, Ryan H Moy
Cancer Chemotherapy and Pharmacology. 2025-01-22
Development, review, and activation of thoracic oncology investigator-initiated trials.
David E Gerber, Claire R Wynters, Tanushree Prasad, Ronny K Schnel, Song Zhang
Clinical Cancer Research. 2025-01-17
Brief Report: Phase II Clinical Trial of Atezolizumab in Advanced Nonsmall Cell Lung Cancer Patients Previously Treated With PD-1-Directed Therapy.
Dylan Fortman, Hong Wang, Robert VanderWeele, Terry Evans, James G Herman
Clinical Lung Cancer. 2025-01-01

Journal Articles

PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer
Liza C Villaruz, Mark A Socinski, Molecular Diagnosis & Therapy

Press Mentions

Asymptomatic Brain Metastases in EGFR-Mutant NSCLCDecember 20th, 2024
Treatment of Oligometastatic EGFR-Mutant Lung CancerNovember 22nd, 2024
Carboplatin, Pemetrexed, and Atezolizumab in Patients with Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Untreated Brain MetastasesFebruary 27th, 2023
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member